Overview

Randomized Study Comparing Tamoxifen vs. Tamoxifen + Aminoglutethimide in Postmenopausal Receptor-positive Patients

Status:
Completed
Trial end date:
2000-03-01
Target enrollment:
Participant gender:
Summary
Primarily, this clinical investigation compared the efficacy of tamoxifen + aminoglutethimide vs. tamoxifen alone in terms of prognosis (overall survival) in postmenopausal patients with potentially curative, operated hormone receptor-positive breast cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Austrian Breast & Colorectal Cancer Study Group
Collaborator:
AstraZeneca
Treatments:
Aminoglutethimide
Tamoxifen